Home > PJ (current issue) > Letters | Search

PJ Online homeThe Pharmaceutical Journal
Vol 276 No 7393 p344
25 March 2006

This article
Reprint   Photocopy

PDF 50K, Acrobat Reader

Letters

· EPS
· Public health
· Supervision
· Assisted dying
· Paracetamol
· FDCs
· Branded prescribing
· Methadone mixture
· Incontinence products
· CPD
· The Society (2)


Letters to the Editor

Electronic prescription service (EPS)

Is this system safe?

From Mr C. Morris, MRPharmS

Having now read the “Connecting for health” pamphlet from the NHS on the electronic prescription service, I have to say that I am deeply worried. I thought that GPs would send us the prescriptions in an e-mail-type format and the thought of that filled me with trepidation. How many people out there have had problems with lost or corrupted e-mails?

But no, the system seems to be that GPs produce a prescription and send it to a central NHS server. We then have to log on to that server and retrieve it. Can I ask in how many ways that system could break down? With thousands of prescriptions being sent to and retrieved from this server every day, I assume that it will be a server of the highest quality, maintained to the highest degree. But of course it will be — it is being paid for by the NHS. Is anyone out there as scared as I am?

The pamphlet also points out that the system will print labels directly from the prescription. I do not know about anyone else, but I pick up most errors from GPs as I am labelling. And, what about interaction checks and notes, such as “Mrs Miggins must have atenolol in a yellow packet?” Will all this be catered for, or is it yet again another system that is destined to be calculated as a success by the amount of time it saves GPs? How about a system that makes things safer for the patient or even the pharmacist?

And, by the way, more convenient does not always mean safer. Look how long monitored dosage systems have been running: nursing and residential homes still seem to have a problem giving the right medicine to the right resident. If systems are made more convenient, it can often seem more convenient to let the less trained staff do the more vital work.

Yes, the old paper system may need overhauling but who is testing the new systems and who gets to say how they go about this?

Chris Morris
Newquay, Cornwall

 

TIM DONOHOE, group programme director at the electronic prescription service, NHS Connecting for Health, responds:

The electronic prescription service (EPS) has undergone a rigorous design, test and build process to ensure that the new system is capable of coping with the 1.3 million prescriptions handled each day across England. This process has been informed by the creation of a number of user groups, comprising GPs, pharmacists and patients, who meet regularly to discuss specific issues.

In order to reduce the probability of any implementation issues affecting patients, the EPS is being introduced alongside the existing paper-based system. Initially, this will allow users to become familiar with the new software and processes before any significant changes affecting patients are introduced.

The concern that labels will be printed directly from the prescription is factually incorrect; prescription data will be presented on screen for the pharmacist to check before they print the label. Interaction checking within pharmacy systems is not part of the EPS specification. Therefore, the interaction checking already undertaken by pharmacy systems is not impacted by the introduction of the EPS.

The EPS will save time for GPs with regard to administering prescriptions, but will also bring a range of other benefits for patients and pharmacists alike. From a pharmacy perspective, it will reduce the possibility of incorrect medicines being dispensed to patients, by alleviating the need to manually input prescription data, and also give scope to improve pharmacy workflow and stock control.

More information about the EPS can be found at www.connectingforhealth.nhs.uk/eps

Send your letter to The Editor

Next Topic (Public health)

Back to Top


©The Pharmaceutical Journal